Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 3/20 | 0.80 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.80 |
| ▸ | CYP4Z1 | Q86W10 | 3/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.49 |
| ▸ | CYP4F11 | Q9HBI6 | 1/20 | 0.48 |
| ▸ | CYP4F12 | Q9HCS2 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.45 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.45 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.45 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL68902 | 0.92 | CYP4F2 (0.85) | CYP4F2CYP4A11CYP4Z1TDP1HRH3 | |
| SCHEMBL22334798 | 0.89 | CYP4F2 (0.65) | CYP4F2CYP4A11CYP4Z1TDP1CYP4F11 | |
| SCHEMBL22098222 | 0.89 | CYP4F2 (1.00) | CYP4F2CYP4A11CYP4Z1TDP1HRH3 | |
| SCHEMBL27937264 | 0.88 | CYP4F2 (0.63) | CYP4F2CYP4A11CYP4Z1TDP1CYP4F11 | |
| SCHEMBL21171917 | 0.88 | CYP4F2 (0.63) | CYP4F2CYP4A11CYP4Z1LMNAL3MBTL1 | |
| SCHEMBL879130 | 0.87 | CYP4F2 (0.77) | CYP4F2CYP4A11CYP4Z1TDP1HRH3 | |
| SCHEMBL11437256 | 0.87 | CYP4F2 (0.77) | CYP4F2CYP4A11CYP4Z1TDP1HRH3 | |
| SCHEMBL363982 | 0.87 | CYP4F2 (0.77) | CYP4F2CYP4A11CYP4Z1TDP1HRH3 | |
| SCHEMBL10206072 | 0.87 | CYP4F2 (0.77) | CYP4F2CYP4A11CYP4Z1TDP1HRH3 | |
| SCHEMBL304455 | 0.85 | CYP4F2 (0.74) | CYP4F2CYP4A11CYP4Z1TDP1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11365192-B2 | Pyridine compound substituted with azole | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2022-06-21 | — | — | US | disclosed |
| US-11365192-B2 | Pyridine compound substituted with azole | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2022-06-21 | — | — | US | disclosed |
| US-20210122741-A1 | PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2021-04-29 | — | — | US | disclosed |
| US-20210122741-A1 | PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2021-04-29 | — | — | US | disclosed |
| EP-3666766-A1 | PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE | Taisho Pharmaceutical Co., Ltd. (JP) | 2020-06-17 | — | — | EP | disclosed |
| EP-3666766-A1 | PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE | Taisho Pharmaceutical Co., Ltd. (JP) | 2020-06-17 | — | — | EP | disclosed |
| US-10662170-B2 | Substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type II diabetes | JANSSEN PHARMACEUTICA NV (BE) | 2020-05-26 | — | — | US | disclosed |
| CN-110914254-A | Azole-substituted pyridine compound | 大正制药株式会社 | 2020-03-24 | — | — | CN | disclosed |
| US-10195178-B2 | GPR40 agonists in anti-diabetic drug combinations | JANSSEN PHARMACEUTICA NV (BE) | 2019-02-05 | — | — | US | disclosed |
| US-10131648-B2 | Substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type II diabetes | JANSSEN PHARMACEUTICA NV (BE) | 2018-11-20 | — | — | US | disclosed |
| EP-1737826-A1 | ALPHA-4 INTEGRIN MEDIATED CELL ADHESION INHIBITORS FOR THE TREATMENT OR PREVENTION OF INFLAMMATORY DISEASES | TANABE SEIYAKU CO., LTD. (JP) | 2007-01-03 | — | — | EP | disclosed |
| US-20050288337-A1 | Novel compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2005-12-29 | — | — | US | disclosed |
| CN-1688548-A | Process for preparing quinolin antibiotic intermediates | TANABE SEIYAKU CO (JP) | 2005-10-26 | — | — | CN | disclosed |
| WO-2005075438-A1 | ALPHA-4 INTEGRIN MEDIATED CELL ADHESION INHIBITORS FOR THE TREATMENT OR PREVENTION OF INFLAMMATORY DISEASES | TANABE SEIYAKU CO., LTD. (JP) | 2005-08-18 | — | — | WO | disclosed |
| EP-1539696-A2 | PROCESS FOR PREPARING QUINOLIN ANTIBIOTIC INTERMEDIATES | TANABE SEIYAKU CO., LTD. (JP) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004014859-A2 | PROCESS FOR PREPARING QUINOLIN ANTIBIOTIC INTERMEDIATES | TANABE SEIYAKU CO., LTD. (JP) | 2004-02-19 | — | — | WO | disclosed |
| US-5180730-A | Pyridylthiomethyl-Substituted Phenols, Antianaphylactic Agents | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1993-01-19 | — | — | US | disclosed |
| US-4933348-A | MEDICINES; ANTAGONISTS OF SLOW REACTING SUBSTANCE OF ANAPHYLAXIS; PROPHYLAXIS AND TREATMENT OF ALLERGIC DISEASES | MASE TOSHIYASU (JP) | 1990-06-12 | — | — | US | disclosed |
| US-4803211-A | Thiadizazole compounds as antagonists of SRS-A | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1989-02-07 | — | — | US | disclosed |
| EP-0214732-A2 | (Substituted benzyl)-thio heterocyclic compounds having a leukotriene-antagonist activity | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1987-03-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210122741-A1 | PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE | CYP2C19, CYP4A11, CYP11B1 | CYP4F2 20/4885CYP4A11 2/4885CYP4Z1 63/4885 |
| US-20050288337-A1 | Novel compounds | ITGB4, ITGA4, ITGB5 | CYP4F2 1416/4885CYP4A11 2202/4885CYP4Z1 2005/4885 |
| US-10195178-B2 | GPR40 agonists in anti-diabetic drug combinations | GPR119, GLP1R, GPR65 | CYP4F2 1212/4885CYP4A11 726/4885CYP4Z1 2732/4885 |
| US-11365192-B2 | Pyridine compound substituted with azole | CYP2C19, CYP4A11, CYP11B1 | CYP4F2 20/4885CYP4A11 2/4885CYP4Z1 63/4885 |
| US-10662170-B2 | Substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type II diabetes | GPR119, GPR52, GPR65 | CYP4F2 1157/4885CYP4A11 693/4885CYP4Z1 3813/4885 |
| US-10131648-B2 | Substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type II diabetes | GPR119, GPR52, GPR65 | CYP4F2 1157/4885CYP4A11 693/4885CYP4Z1 3813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.